Targretin bexarotene capsules: Phase II data; Marketed to treat refractory cutaneous T cell lymphoma (CTCL)

In a 54-patient Phase II study that LGND said was terminated

Read the full 111 word article

How to gain access

Continue reading with a
two-week free trial.